Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

Journal Article · · J. Urol.; (United States)
OSTI ID:6071213

Serum prostate specific antigen was determined (Yang polyclonal radioimmunoassay) in 183 men after radiation therapy for adenocarcinoma of the prostate. A total of 163 men had received 7,000 rad external beam radiotherapy and 20 had been implanted with iodine-125 seeds. Only 11 per cent of these 183 patients had undetectable prostate specific antigen levels at a mean interval of 5 years since completion of radiotherapy. Prostate specific antigen levels after radiotherapy were directly related to initial clinical stage and Gleason score before treatment. Multiple prostate specific antigen determinations were performed with time in 124 of 183 patients. During year 1 after radiotherapy prostate specific antigen levels were decreasing in 82 per cent of the patients but only 8 per cent continued to decrease beyond year 1. Of 80 patients observed greater than 1 year after completion of radiotherapy 51 per cent had increasing values and 41 per cent had stable values. Increasing prostate specific antigen values after radiotherapy were correlated with progression to metastastic disease and residual cancer on prostate biopsy. Total serum acid phosphatase levels were poorly related to prostate specific antigen levels, were less effective in discriminating patients with metastatic disease and provided no additional information beyond that provided by prostate specific antigen.

Research Organization:
Stanford Univ. Medical Center, CA (USA)
OSTI ID:
6071213
Journal Information:
J. Urol.; (United States), Journal Name: J. Urol.; (United States) Vol. 141:5; ISSN JOURA
Country of Publication:
United States
Language:
English

Similar Records

Teletherapy for stage C adenocarcinoma of the prostate
Journal Article · Thu Jul 01 00:00:00 EDT 1982 · J. Urol.; (United States) · OSTI ID:6709764

Long-Term Results of a Phase II Trial of Ultrasound-Guided Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate (RTOG 98-05)
Journal Article · Thu Sep 01 00:00:00 EDT 2011 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21587707

Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05)
Journal Article · Sun Dec 31 23:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20850292